Anthropic is diving into biological sciences with the acquisition of Coefficient Bio, a secretive startup specializing in artificial intelligence (AI)-driven drug discovery.
The deal, valued at approximately $400 million in stock, underscores a growing trend of frontier AI labs moving beyond general-purpose chatbots toward specialized scientific applications.
According to reports from Newcomer and The Information, the acquisition incorporates a lean team of fewer than 10 specialists, many of whom are alumni of Genentech’s elite computational biology unit, Prescient Design.
While the price tag is significant, the deal represents just 0.1% dilution for Anthropic, which was valued at $380 billion following its Series G funding round in February. For that price, Anthropic is buying more than just software; it is acquiring a deep bench of specialized talent capable of building biological foundation models from the ground up.
Until now, Anthropic’s healthcare strategy — dubbed “Claude for Life Sciences” — focused on adapting existing models to help researchers manage data. The Coefficient Bio acquisition suggests a shift toward more fundamental science. The startup’s founders, Samuel Stanton and Nathan C. Frey, previously described their mission as creating “artificial superintelligence for science.”
The acquisition highlights a massive talent migration. As legacy pharmaceutical giants like Roche-owned Genentech restructure to embed digital capabilities, their top-tier researchers are fleeing to AI-native startups.
Stanton and Frey are at the center of this exodus. Stanton, a data science PhD from NYU, was a key architect of biological deep learning libraries at Genentech. Frey, a materials science PhD and former National Defense Fellow, led Genentech’s collaboration with NVIDIA Corp. and authored high-impact research on generative modeling for drug discovery. Their recruitment pitch in early 2026 was “ushering biopharma into the Intelligence Age.”
The Coefficient Bio team will be folded into Anthropic’s Healthcare and Life Sciences division, led by Eric Kauderer-Abrams. The goal is to evolve Claude from a writing assistant into a specialized laboratory partner capable of drafting R&D plans, navigating complex clinical regulatory strategies, and discovering novel drug candidates.
The acquisition places Anthropic in direct competition with other heavily funded ventures like Xaira Therapeutics, which launched with $1 billion to pursue similar AI-first drug development.
By absorbing a team that was already building a platform for “walk-jump sampling” and discrete generative modeling, Anthropic is betting that the next great breakthrough in AI won’t be a better poem or a cleaner line of code, but a life-saving medicine.
Anthropic’s previous acquisitions include Bun, a JavaScript runtime, and Vercept, an AI agent computer-use startup.
